Eu Bans Drugs

Prime Minister Narendra Modi's office wrote to the EU Trade Commissioner to intervene when the ban on around 700 pharmaceutical products was formalised in May, two government sources in New Delhi said.

India's business loss arising from the European Union's ban on 700 generic drugs is likely to be around $1.2 billion, according to industry body Pharmexcil.

The largest EU-wide suspension of sales and distribution of generic drugs ordered by the European Commission will come into effect on August 21 and it will be applicable to all 28 member nations, according to Germany's drug regulator, the Federal Institute for Medicines and Medical Products (BfArM).

The European Union banned the party drug nicknamed "bath salts" and other so-called legal highs on Thursday that have been linked to nearly 150 deaths.

Days after the US Food and Drug Administration (FDA) banned import of Ranbaxy products to America from its Toansa plant, health regulators of the EU and the UK have said they are evaluating the FDA inspection findings to assess if deviations from good manufacturing practice (GMP) have any implication in their markets.

Prime Minister Narendra Modi's office wrote to the EU Trade Commissioner to intervene when the ban on around 700 pharmaceutical products was formalised in May, two government sources in New Delhi said.

India's business loss arising from the European Union's ban on 700 generic drugs is likely to be around $1.2 billion, according to industry body Pharmexcil.

The largest EU-wide suspension of sales and distribution of generic drugs ordered by the European Commission will come into effect on August 21 and it will be applicable to all 28 member nations, according to Germany's drug regulator, the Federal Institute for Medicines and Medical Products (BfArM).

The European Union banned the party drug nicknamed "bath salts" and other so-called legal highs on Thursday that have been linked to nearly 150 deaths.

Days after the US Food and Drug Administration (FDA) banned import of Ranbaxy products to America from its Toansa plant, health regulators of the EU and the UK have said they are evaluating the FDA inspection findings to assess if deviations from good manufacturing practice (GMP) have any implication in their markets.